Sponsor

Tanabe Pharma Corporation

Clinical research sponsor

Published trials56
Recruiting shown0
Roles2
SourceClinicalTrials.gov

Clinical trials

56 shown
Efficacy and Safety of Canagliflozin (TA-7284) in Patients With Diabetic NephropathyNCT03436693 · lead sponsor · 2018-02-15
COMPLETED
Efficacy and Safety of Teneligliptin in Combination With Metformin in Chinese Patients With Type 2 Diabetes MellitusNCT02924064 · lead sponsor · 2016-09-01
COMPLETED
Efficacy and Safety of Teneligliptin in Chinese Patients With Type 2 Diabetes MellitusNCT02916706 · lead sponsor · 2016-09-01
COMPLETED
An Extended Treatment Study of MT-3995 in Patients With Diabetic NephropathyNCT02676401 · lead sponsor · 2016-02-01
COMPLETED
Efficacy and Safety of MT-3995 in Patients With Diabetic NephropathyNCT02517320 · lead sponsor · 2015-07-01
COMPLETED
Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Canagliflozin)NCT02354235 · lead sponsor · 2015-01-01
COMPLETED
Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Teneligliptin)NCT02354222 · lead sponsor · 2015-01-01
COMPLETED
Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes MellitusNCT02622113 · lead sponsor · 2014-12-01
COMPLETED
Safety Study of MT-4666 in Subjects With Alzheimer's DiseaseNCT02327182 · lead sponsor · 2014-12-01
TERMINATED
Comparative Oral Bioavailability Study of MT-1303NCT02310048 · lead sponsor · 2014-11-01
COMPLETED
Mass Balance Study of MT-1303NCT02293967 · lead sponsor · 2014-09-01
COMPLETED
Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With GLP-1 Analogue in Patients With Type 2 Diabetes MellitusNCT02227849 · lead sponsor · 2014-08-01
COMPLETED
Efficacy and Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes MellitusNCT02220920 · lead sponsor · 2014-08-01
COMPLETED
Long-Term Safety Study of MT-2412 in Japanese Patients With Type 2 DiabetesNCT02220907 · lead sponsor · 2014-08-01
COMPLETED
Safety, Tolerability and Pharmacokinetic Study of MT-3995 at a Low Dose in Subjects With Diabetic NephropathyNCT02205372 · lead sponsor · 2014-07-01
COMPLETED
Efficacy and Safety Study of Teneligliptin (MP-513) in Combination With Insulin in Patients With Type 2 DiabetesNCT02081599 · lead sponsor · 2014-01-01
COMPLETED
Extension Study of MT-1303NCT01890655 · lead sponsor · 2013-08-01
COMPLETED
Safety, Tolerability and Pharmacokinetic Study of MT-3995 in Subjects With Diabetic NephropathyNCT01889277 · lead sponsor · 2013-07-01
COMPLETED
Dose-finding Study of MT-1303NCT01742052 · lead sponsor · 2013-01-01
COMPLETED
A Study to Evaluate Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of MT-3995 in Type II Diabetic Nephropathy Subjects With Albuminuria and Moderately Decreased GFRNCT01756716 · lead sponsor · 2012-12-01
COMPLETED
Safety and Efficacy of MT-4666NCT01764243 · lead sponsor · 2012-11-01
COMPLETED
A Study to Evaluate Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of MT-3995 in Type II Diabetic Nephropathy Subjects With AlbuminuriaNCT01756703 · lead sponsor · 2012-11-01
COMPLETED
Long-Term Study of MP-214 in Patients With SchizophreniaNCT01626872 · lead sponsor · 2012-09-01
COMPLETED
A Long-Term Study of MP-214 in Patients With Receiving Multiple Drugs SchizophreniaNCT01626885 · lead sponsor · 2012-05-01
COMPLETED
A Pharmacokinetic Study of MP-214 in Patients With SchizophreniaNCT01626859 · lead sponsor · 2012-05-01
COMPLETED
A Long-Term Study of MP-214 in Patients With Chronic Phase or Elderly SchizophreniaNCT01625897 · lead sponsor · 2012-05-01
COMPLETED
Safety and Efficacy of MP-214 in Patients With SchizophreniaNCT01625000 · lead sponsor · 2012-05-01
COMPLETED
A Study to Evaluate the PK/PD and Safety of TA-7284 in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal ImpairmentNCT01512849 · lead sponsor · 2012-01-01
COMPLETED
Efficacy and Safety Study of TA-7284 in Patients With Type 2 DiabetesNCT01413204 · lead sponsor · 2011-07-01
COMPLETED
Long-Term Safety Study of TA-7284 in Patients With Type 2 Diabetes MellitusNCT01387737 · lead sponsor · 2011-05-01
COMPLETED
Long-term Safety Study of MP-513 in Patients With Type 2 DiabetesNCT01301833 · lead sponsor · 2011-02-01
COMPLETED
Efficacy and Safety Study of MP-435 in Combination With Methotrexate (MTX) in Patients With Rheumatoid ArthritisNCT01143337 · lead sponsor · 2010-06-01
COMPLETED
Pharmacokinetic/Pharmacodynamic Study of MP-513 With Type 2 Diabetes MellitusNCT01072331 · lead sponsor · 2010-02-01
COMPLETED
Efficacy and Safety Study of MP-513 in Combination With Thiazolidinedione in Patients With Type 2 DiabetesNCT01026194 · lead sponsor · 2009-12-01
COMPLETED
An Efficacy, Safety, and Tolerability Study for TA-7284 in Patients With Type 2 DiabetesNCT01022112 · lead sponsor · 2009-11-01
COMPLETED
Monotherapy Study of MP-513 in Patients With Type 2 DiabetesNCT00998881 · lead sponsor · 2009-09-01
COMPLETED
Efficacy and Safety Study of MP-513 in Combination With Sulfonylurea in Patients With Type 2 DiabetesNCT00974090 · lead sponsor · 2009-09-01
COMPLETED
Efficacy and Safety of MP-513 in Combination With Metformin in Patients With Type 2 DiabetesNCT00971243 · lead sponsor · 2009-08-01
COMPLETED
Long-term Safety Study of MP-513 as Monotherapy or in Combination With Sulfonylurea in Japanese Type 2 Diabetic PatientsNCT02314637 · lead sponsor · 2009-08-01
COMPLETED
Safety, Pharmacokinetics and Pharmacodynamics of TA-7284 in Type 2 Diabetic PatientsNCT00707954 · lead sponsor · 2008-06-01
COMPLETED
Safety, Pharmacokinetics and Efficacy Study of MP-214 in Patients With SchizophreniaNCT00862992 · lead sponsor · 2008-04-01
COMPLETED
Efficacy and Safety Study of MP-513 in Patients With Type 2 DiabetesNCT00628212 · lead sponsor · 2008-01-01
COMPLETED
Safety and Efficacy of MCC-257 in the Treatment of Diabetic PolyneuropathyNCT00307749 · lead sponsor · 2006-03-01
COMPLETED
Efficacy and Safety Study of MCI-196 in Patients With Type 2 DiabetesNCT00497198 · lead sponsor · 2005-10-01
COMPLETED
Efficacy and Safety of Increased Dose of TA-650(Infliximab) in Patients With Rheumatoid ArthritisNCT00691028 · lead sponsor · 2005-09-01
COMPLETED
A Phase 1 Study to Explore the Cardiac Pharmacodynamics of MT-1303NCT02193217 · lead sponsor
COMPLETED
Tryptophan MRI in People With Schizophrenia and Healthy ControlsNCT02067975 · collaborator · 2014-08-14
COMPLETED
A Safety and Efficacy Study of Golimumab (CNTO 148) in Patients With Active Rheumatoid Arthritis Despite Methotrexate TherapyNCT00727987 · collaborator · 2008-05-01
COMPLETED
A Safety and Efficacy Study of Golimumab (CNTO148) in Patients With Active Rheumatoid Arthritis (RA)NCT00771251 · collaborator · 2008-05-01
COMPLETED
An Extension Study of the Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing Multiple SclerosisNCT00670449 · collaborator · 2008-04-01
COMPLETED
Efficacy and Safety of FTY720 in Patients With Relapsing Multiple Sclerosis (MS)NCT00537082 · collaborator · 2007-09-01
COMPLETED
Enhancement of in-Vitro GC Function in Patients With COPDNCT00241631 · collaborator · 2006-04-01
COMPLETED
Long-term Study of Safety and Efficacy of Roflumilast in Japanese Patients Older Than 40 Years With Chronic Obstructive Pulmonary Disease (APTA-2217-08)NCT00246935 · collaborator · 2005-05-01
COMPLETED
Long-term Study of Safety and Efficacy of Roflumilast in Japanese Patients With Bronchial Asthma (20 to 71 y) (APTA-2217-07).NCT00246922 · collaborator · 2004-12-01
COMPLETED
Efficacy and Safety of Roflumilast in Japanese Patients Older Than 40 Years With Chronic Obstructive Pulmonary Disease (APTA-2217-06)NCT00242294 · collaborator · 2004-11-01
COMPLETED
Efficacy and Safety of Roflumilast in Japanese Patients With Bronchial Asthma (20 to 70 y) (APTA-2217-05).NCT00242307 · collaborator · 2004-05-01
COMPLETED

Sponsor roles

lead sponsor46
collaborator10

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.